Abstract
Pyoderma gangrenosum (PG) is a difficult-to-treat inflammatory skin condition that affects inflammatory bowel disease (IBD) patients. There is no standardized approach for PG treatment.1 We report the results of 3 patients with Crohn's disease (CD) and refractory PG who had failed several therapies with biologics and were started on tofacitinib for severe inflammatory arthritis with resolution of their PG.
Copyright © 2019 AGA Institute. Published by Elsevier Inc. All rights reserved.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Female
-
Histocytochemistry
-
Humans
-
Immunohistochemistry
-
Immunologic Factors / administration & dosage*
-
Male
-
Middle Aged
-
Piperidines / administration & dosage*
-
Protein Kinase Inhibitors / administration & dosage*
-
Pyoderma Gangrenosum / drug therapy*
-
Pyoderma Gangrenosum / pathology*
-
Pyrimidines / administration & dosage*
-
Pyrroles / administration & dosage*
-
Skin / pathology
-
Treatment Outcome
-
Young Adult
Substances
-
Immunologic Factors
-
Piperidines
-
Protein Kinase Inhibitors
-
Pyrimidines
-
Pyrroles
-
tofacitinib